No. 2089 May 5 & 12, 2008
PHARMA JAPAN is a must read for every busy executive who needs to keep up with the world's second largest health care market.
P. Reed Maurer
 　　　　　　　　　　　　
Employees Are BI's Most Important Asset: Chairman Banchi
 p 1
Eisai Will Recover Investment in MGI Pharma by 2016: Mr Naito
 p 3
Nippon Shinyaku Licenses PAH Treatment to Actelion p 4
Astellas Licenses BACE Inhibitors from CoMentis p 5
Kyorin Licenses Flutiform from SkyePharmap 5
Nexavar to Be Transiently Excluded from DPC System p 8
JPMA to Propose Exemption from Price-cutting Based on Average Price Discrepancy Rate p 8
Council Proposes Introduction of "Emergency Budgets for National Projects" in FY2009 p 14
President Hatori Shows Confidence in Vigorous Growth of SSP from FY2009 p 19

PHARMA JAPAN witnesses important events taking place in the second-largest pharmaceutical market on a comprehensive, weekly basis.



│Information│Order Here│Preview│Ads│Table of Contents│Books│